ARTICLE | Company News
DRAX submits NDS for Ziconotide
December 14, 2000 8:00 AM UTC
Draxis Health (DRAX; TSE:DAX) submitted an NDS in Canada for Ziconotide, an N-type neuronal calcium channel blocker to treat chronic intractable pain. DRAX licensed Canadian rights to Zicotonide from ...